Prosecution Insights
Last updated: October 01, 2026

Examiner: SAMSELL, RILLA MARIE

Tech Center 1600 • Art Units: 1624 1626 1653

This examiner grants 71% of resolved cases

Analysis

Rilla Marie Samsell has resolved 88 cases in Tech Center 1600. The examiner has an allowance rate of 71.6 percent. This rate suggests a fair chance of success in Art Unit 1624. The 71.6 percent allowance rate indicates that the examiner is open to granting patents when the technical merits are clearly established.

The interview lift is 15.3 percent. This positive lift indicates that interviews are a helpful tool for advancing prosecution and overcoming potential rejections. A 15.3 percent increase in the probability of allowance makes direct communication a valuable part of the overall strategy for applications assigned to this examiner.

The median days to allowance is 1187. This timeframe represents the typical path to grant for successful cases. Applicants should plan for a prosecution cycle of this length and consider using the 15.3 percent interview lift to navigate the 1187 day pendency more effectively.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

70.8%
Allow Rate
+10.8% vs TC avg
117
Total Applications
+4.6%
Interview Lift
1193
Avg Prosecution Days
Based on 89 resolved cases, 2023–2026

Rejection Statute Breakdown

7.0%
§101 Eligibility
20.9%
§102 Novelty
24.3%
§103 Obviousness
32.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18785641 WEEKLY REGIMEN FOR HIV Non-Final OA Gilead Sciences, Inc.
18578205 USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF HYPERTENSION IN NON-HUMAN MAMMALS Final Rejection BOEHRINGER INGELHEIM VETMEDICA GMBH
18289283 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION Non-Final OA MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
18775510 USES AND METHODS FOR PROMOTING INCREASED MITOCHONDRIAL MASS AND FUNCTION Non-Final OA Sanford Burnham Prebys Medical Discovery Institute
18043419 COMPOUND FOR INHIBITING MUTANT EGFR AND USE THEREOF Final Rejection East China University of Science and Technology

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month